CLINICAL_TRIALS
research
· 2026-04-24
Clinical Trial Update: REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome [Phase 3]
Summary
Ionis Pharmaceuticals reports a Phase 3 trial (REVEAL) of ION582 for Angelman syndrome, currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Angelman Syndrome | Phase 3 | Status: RECRUITING